Yet to find a partner ready to commit to carrying its herpes immunotherapy, GEN-003, through phase III, Cambridge, Mass.-based Genocea Biosciences Inc. is putting the program on hold as it refocuses its energies on a neoantigen cancer vaccine for which it expects to file an investigational new drug application by early 2018.